About
Biologics for Skin Disease
Areas of Focus
Categories
Biologics & BiopharmaceuticalBoston & New England
Team (21)
Alan Lada
VP, Investor Relations
Oruka Therapeutics
executive
Andrew Blauvelt, MD, MBA
Chair, Scientific Advisory Board
Oruka Therapeutics
board_chair
Arjun Agarwal
SVP, Finance
Oruka Therapeutics
team_member
Cameron Turtle, DPhil
CEO, Spyre Therapeutics
Oruka Therapeutics
executive
Carl Dambkowski, MD
CMO, Apogee Therapeutics
Oruka Therapeutics
executive
Christopher Finch
VP, Corporate Development & Strategy
Oruka Therapeutics
executive
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
128
By Phase
PHASE2: 1PHASE1: 2
By Status
ACTIVE_NOT_RECRUITING: 2RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07090330Lead Sponsor
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
PHASE2Recruiting
80 participants
Started: Jul 18, 2025 · Completed: May 31, 2027
NCT06944379Lead Sponsor
ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose
PHASE1Active, not recruiting
24 participants
Started: May 19, 2025 · Completed: Jan 31, 2027
NCT06698939Lead Sponsor
ORKA-001 in Healthy Volunteers
PHASE1Active, not recruiting
24 participants
Started: Dec 19, 2024 · Completed: Jun 30, 2026
Locations (1)
Headquarters
Waltham, MA, United States
Map
Loading map...